Shattuck Labs, Inc. Proceeds from Issuance of Redeemable Convertible Preferred Stock
Shattuck Labs, Inc. (STTK) reported Proceeds from Issuance of Redeemable Convertible Preferred Stock of $0 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock · last filed 2021-05-10
- Shattuck Labs, Inc. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Shattuck Labs, Inc. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2020-03-31 was $34.43M.
| Period end | Proceeds from Issuance of Redeemable Convertible Preferred Stock 3 month |
|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 |
| 2020-03-31 | $34.43M 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |